Akero Therapeutics reported that at 96 weeks, 39% of patients who received the 50 mg dose of efruxifermin achieved improvement in fibrosis, or liver scarring, caused by the fatty liver disease MASH. This study previously failed to achieve statistically significant improvement at 36 weeks, but Akero executives say the latest results show that longer dosing matters.
Akero Therapeutics’ preliminary Phase 2b data show that treatment with its MASH drug, efruxifermin, continued to distance itself from a placebo measured at nearly two years of treatment. The latest Akero data build on six-month results reported in 2022.
A new report from Relatient, A Data-Driven Guide to Patient Access Succes, highlights how focusing on data accuracy and relevance can enhance the performance of healthcare practices.
Akero Therapeutics’ experimental NASH drug, efruxifermin, met the main and secondary goals of Phase 2b clinical trial. The biotech will still need to show that the drug’s efficacy can hold up in a pivotal study, but the results so far are a positive sign for the NASH field, which has been marred by clinical trial failures.